Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Expert Addresses Therapeutic Updates for Breast Cancer Subtypes

March 22nd 2019

William J. Gradishar, MD, discusses the latest updates in HER2-negative advanced breast cancer and the role of molecular assays in this space.

Dr. Ward on Multigene Testing in Breast Cancer

March 22nd 2019

John H. Ward, MD, discusses his preferences in multilane testing for patients with hormone receptor–positive, node-negative breast cancer.

Dr. Rao on Treatment De-Escalation in HR+/HER2- Breast Cancer

March 20th 2019

Ruta D. Rao, MD, an associate professor at Rush University Medical Center, discusses therapy de-escalation for patients with early-stage hormone receptor (HR)-positive, HER2-negative breast cancer.

For This Giant of Cancer Care, a Holistic Approach Was Always in the Treatment Plan

March 20th 2019

A 2018 Giants of Cancer Care® award winner for Supportive, Palliative Geriatric Care, Patricia A. Ganz, MD has spent much of her life working to improve the quality of care for patients with cancer.

When a Measure of Significance Is Not All That Significant

March 20th 2019

The term statistically significant is almost certainly beautiful music to the ears of clinical investigators and pharma/biotech companies. However, concern develops when one inquires how the most common test of significance, the P value, is used in clinical investigative efforts and whether at times this is more harmful than helpful within the domain of cancer medicine.

Spectrum Withdraws Application for Eflapegrastim in Chemo-Induced Neutropenia

March 16th 2019

Spectrum Pharmaceuticals has voluntarily withdrawn their biologics license application for eflapegrastim, due to the company needing more time to complete the FDA’s request for additional manufacturing-related information.

UK Grants EAMS Positive Opinion to Atezolizumab Combo in Frontline TNBC

March 15th 2019

The United Kingdom’s Medicines and Healthcare Products Regulatory Agency has granted an Early Access to Medicines Scheme positive scientific opinion to atezolizumab in combination with nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.

CTC Surveillance in Early-Stage Breast Cancer: What's Next?

March 14th 2019

Blood-based biomarkers offer great potential for use in the management of breast and other cancers.

A New Trio of Genes Enters the Risk Assessment Equation in Hereditary Breast Cancer

March 14th 2019

David M. Euhus, MD, discusses a new trio of genes entering the risk assessment equation in hereditary breast cancer.

Dr. Chagpar on Management of the Axilla in Breast Cancer

March 13th 2019

Anees B. Chagpar, MD, FACS, associate professor, Department of Surgery, Yale School of Medicine, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses the management of the axilla in breast cancer.

Experts Say DCIS Requires Focus on Genomics and Microenvironment

March 13th 2019

Identifying patients with ductal carcinoma in situ who are more likely to develop invasive breast cancer remains a challenge, despite decades of research and the development of stratification methods to predict progression and recurrence.

Dr. Litton on the Impact of PARP Inhibitors in Breast Cancer

March 13th 2019

Jennifer Litton, MD, associate professor in the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the impact of PARP inhibitors in breast cancer.

Dr. Borgen on the Opioid Crisis in Breast Cancer

March 12th 2019

Patrick I. Borgen, MD, chair, Department of Surgery, director, Breast Cancer, Maimonides Medical Center, discusses the opioid crisis related to the treatment of patients with breast cancer.

New Strategies Shift Landscape in HR+ Metastatic Breast Cancer

March 12th 2019

There has been much progress in the treatment of estrogen receptor-positive metastatic breast cancer over the past 40 years, and novel therapies are further expanding therapeutic options.

Circulating Tumor DNA Testing Shows Growing Potential for Clinical Utility in Breast Cancer

March 12th 2019

CtDNA will continue to gain importance in precision oncology as physicians continue to uncover the role and interplay of genomic alterations that promote tumor heterogeneity.

Bridging the Knowledge Gap Between Biosimilars and Biologics in Breast Cancer

March 11th 2019

Since 2006, the European Medicines Agency has granted marketing authorization for more than 40 biosimilars, and, in less than 4 years, the FDA has approved 17, yet the knowledge gap in the understanding of biosimilarity poses a unique challenge to the agents’ assimilation into clinical practice and possible impact on access and cost savings, experts say.

Excitement Grows About Immunotherapy Potential in Breast Cancer

March 10th 2019

Although the first checkpoint inhibitor has just been approved for patients with breast cancer, findings from dozens of ongoing studies may eventually change the paradigm for large subsets of those with the malignancy.

Antibody-Drug Conjugates Make Headway in TNBC

March 10th 2019

The development of antibody-drug conjugates represents a promising strategy for patients with metastatic triple-negative breast cancer, with early clinical trial results suggesting that novel agents could eventually change the landscape for this patient population.

Awareness Critical for Identifying irAEs Early in Breast Cancer

March 10th 2019

With tremendous advances and the accelerated approval of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer, provider education in identifying associated toxicities from checkpoint inhibitor therapy is critical.

Dr. Rugo on 20-Year Span of Breast Cancer Advancements

March 10th 2019

Hope S. Rugo, MD, director, Breast Oncology and Clinical Trials Education, University of California San Francisco Comprehensive Cancer Center, discusses the therapeutic advancements in the breast cancer space in the past 20 years.